While our in vitro results coupled with the transcriptomic analysis of ACC tumors suggest that a subpopulation of patients that demonstrates high PRMT5 expression along with elevated levels of MYC, MYB and direct targets of lenvatinib may benefit from the treatment that combines lenvatinib and PRT543, further validation in preclinical animal models and clinical settings is required to assess the feasibility of this putative therapeutic strategy. The gene discussed is MYC; the disease is adrenal cortex carcinoma.